IO Biotech
Qin T. is a senior scientist specializing in biomarkers at IO Biotech since April 2022. Prior experience includes a research scientist role at PPD, focusing on functional service partnerships to support GSK Vaccine Development, and a flow cytometry specialist position at MilliporeSigma, where Qin led GLP-compliant testing for regulatory submissions. Other notable roles encompass contributions to oncology therapeutics and diagnostics as a senior scientist at Precision For Medicine, support for IND filing and Phase 1 clinical trials at MacroGenics, and pre-clinical studies of therapeutic proteins at Human Genome Sciences. Earlier experiences include research at GenVec and the University of Minnesota, where Qin developed adenovirus vectors and investigated NK lineage cells. Qin holds a Master of Science in Clinical Laboratory Science/Immunology from the University of Minnesota.
This person is not in any offices
IO Biotech
2 followers
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Their pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules.